Shire Submits Elaprase BLA For Hunter Syndrome
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Shire's Elaprase (idursulfase) could be approved as early as May 2006 for Hunter syndrome if FDA grants the company's request for priority review of the BLA submission, announced Nov. 24